Cognitive Remediation Therapy (CRT) as a treatment enhancer in eating disorders and obsessive compulsive disorders

Completed

• Conditions: én obssesieve compulsieve stoornissen; Eating Disorders and Obssessive Compulsive Disorders; 10014067

• Registration Number: NL-OMON44074
• Lead Sponsor: Altrecht GGZ (Den Dolder)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 192

Inclusion Criteria

ED patients: The ED patients encompass primarily patients with Anorexia nervosa (including those patients that meet some but not all of the diagnostic criteria for AN who are diagnosed as Eating Disorders Not Otherwise Specified ( (clinically referred to as AN) as established by medical experts and verified with the Structured Clinical Interview on axis I DSM V diagnoses (SCID-I; for a structural diagnosis)/ assessed with the aid of the Eating Disorder Examination Interview.;OCD patients: The OCD patients encompass OCD patients of all symptom dimensions (Leckman, Grice, Boardman et al., 1997), as established by medical experts and verified with the Structured Clinical Interview on axis I DSM IV diagnoses (SCID-I; for a structural diagnosis) and should have a Yale- Brown Obsessive-compulsive scale (Goodman, Price, Rasmussen et al., 1989a,1989b) severity score of > 16.;Control participants: The control participants encompass only adult people of whom 50% is matched to the ED patient group and 50%.to the OCD patient group regarding gender and age

Exclusion Criteria

Patients with neurological illness (epilepsia, Parkinson*s disease), co-morbid severe psychiatric disorders (severe major depressive disorder, current psychosis, dependence and abuse of alcohol, drugs), mental deficiency (IQ < 80) and inability to adequately read or speak Dutch will be excluded. Use of anti-depressants will be permitted, provided that dosages are kept constant during the experimental part of the study. Benzodiazepine use will be accepted only when used as sleep medication, since benzodiazepine use might hamper the effect of cognitive treatments.
Control participants with a current episode or history of psychiatric disorders as determined with the MINI interview, with neurological illness, mental deficiency, or an inability to adequately read of speak Dutch will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-Disease specific psychopathology<br /><br>-Quality of ife and daily functioning<br /><br>-Treatment adherence<br /><br>-Cost effectiveness (direct medical costs, indirect costs due to health<br /><br>problems)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-Cognitive flexibility<br /><br>-General psychopathology </p><br>